How to Dose Semaglutide

Standard semaglutide titration runs 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg and 2.0 mg at four-week intervals, with each step held for a minimum of 28 days before escalation. For GI-sensitive research subjects, a slow-titration variant published in Diabetes Care (2025) increased the dose by five pen-clicks weekly rather than stepwise milligram jumps, producing better treatment persistence than standard escalation because the gradual approach allows greater gastric adaptation [1].

The full protocol, slow-titration variant and pen-click conversions are below.

Key Takeaways

• Semaglutide titrates over 16–24 weeks depending on GI tolerance, starting at 0.25 mg and reaching a 2.0 mg weekly ceiling
• Each dose step must be held for a minimum of 28 days to allow steady-state plasma concentrations and gastric adaptation
• The slow-titration variant (doubling the 0.25 mg phase to eight weeks) improves tolerability for GI-sensitive subjects without sacrificing efficacy
• Reconstitution concentration, injection site rotation, and storage at 2–8 °C are critical to dose accuracy and drug stability across the titration series
• Nausea and GI symptoms are transient in most subjects; holding the current dose for four additional weeks rather than retreating typically resolves tolerability issues

What Is Semaglutide and How Does It Work?

Semaglutide is a long-acting GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) with a molecular weight of 4,113.58 Da and an elimination half-life of approximately 165–184 hours. That half-life is the pharmacokinetic basis for once-weekly subcutaneous dosing, it allows steady-state plasma concentrations to build predictably from weekly injections.

The molecule is a 31-amino-acid analogue of native GLP-1, structurally modified with a C18 fatty di-acid chain that drives albumin binding and prolongs systemic exposure.

Agonism at the GLP-1 receptor produces three effects relevant to research dosing models:

• Glucose-dependent insulin secretion from pancreatic β-cells
• Delayed gastric emptying (the dominant driver of the GI adverse-event profile that motivates slow titration)
• Central appetite modulation via GLP-1 receptors expressed in the arcuate nucleus of the hypothalamus

The third pathway underpins the weight-loss endpoints observed across the STEP trial series (2021–2023) because GLP-1 signalling in the hypothalamus reduces hunger signals.

Why the half-life dictates the titration cadence

Steady-state plasma concentrations reach equilibrium after roughly four to five half-lives, meaning 28–35 days. That arithmetic explains why every step in the tirzepatide dosing protocol and in the comparable retatrutide vs semaglutide vs tirzepatide escalation models is held for a minimum of 28 days before the next increase. Each dose reaches equilibrium before advancing.

Standard Semaglutide Titration Schedule (0.25–2 mg)

The canonical semaglutide dosing titration protocol weekly schedule escalates through five fixed phases: 0.25 mg for weeks 1–4, 0.5 mg for weeks 5–8, 1 mg for weeks 9–12, 1.7 mg for weeks 13–16, and 2.0 mg from week 17 onwards. Each step is held for a minimum of 28 days. The ladder below mirrors the STEP 1 (Wilding et al., NEJM, 2021) protocol and the STEP 5 maintenance arm (Garvey et al., Lancet, 2022), which confirmed tolerability of the 2.0 mg ceiling across 104 weeks of continuous administration, no dose-limiting toxicity emerged over that extended period.

Why each phase is held for four weeks

Holding each dose for 28 days serves two pharmacological functions. First, it allows plasma concentrations to approach steady state before the next stimulus; given the 165–184 hour half-life, tolerability can be assessed accurately at equilibrium. Second, it permits tachyphylaxis at the level of gastric emptying, which is the rate-limiting tolerability factor. The delayed-emptying effect attenuates with sustained exposure, reducing nausea incidence at the next step-up because the GI system adapts to the drug's action.

Some research subjects worry that holding a dose for four weeks will delay progress toward the therapeutic endpoint. In practice, rushing through phases increases the risk of intolerance that forces dose reduction or discontinuation, which delays progress far more than a measured titration.

The 2 mg ceiling

2.0 mg weekly is the highest dose validated in registrational trials [1]. STEP 5 demonstrated that this ceiling is sustainable across two years without dose reduction in the majority of completers, no additional safety signals or efficacy gains emerged at higher exposures. Exceeding 2 mg in a research model produces no documented additional receptor occupancy benefit and increases GI adverse-event load disproportionately because higher concentrations amplify delayed gastric emptying. For users cross-referencing class members, see the retatrutide vs semaglutide vs tirzepatide comparison and the parallel how to dose tirzepatide ladder.

Extended Slow-Titration Variant for GI Sensitivity

The slow-titration variant holds 0.25 mg weekly for eight weeks instead of four, then advances through the standard ladder. Total time-to-2 mg extends from 16 to roughly 20–24 weeks. This trades speed for tolerability and is appropriate when a research subject reports persistent nausea, early satiety beyond functional intake, or vomiting at the standard week-5 step-up, these symptoms signal inadequate gastric adaptation.

The mechanistic rationale is gastric tachyphylaxis. The delayed-emptying effect that drives most upper-GI symptoms attenuates with continuous exposure. Doubling the priming window gives that adaptation more runway before the first therapeutic step. A 2025 Diabetes Care report on gradual titration (starting at five pen clicks and increasing by five clicks weekly to target dose) found improved treatment persistence versus standard escalation [1]. This is the closest published proxy for the slow-titration logic applied here because both approaches prioritise gradual receptor engagement over rapid escalation. Quantified head-to-head nausea incidence for an 8-week 0.25 mg hold versus the 4-week standard is not currently published. The 2022 SUSTAIN-class observation of approximately 44% nausea incidence on standard titration is mechanistically relevant but predates the gradual-titration cohort data.

Some subjects worry that an eight-week hold at the starting dose will not produce any therapeutic effect. The 0.25 mg phase is sub-therapeutic by design; the extended hold allows the GI system to adapt without the confounding variable of escalating doses, making the transition to 0.5 mg (the first therapeutic step) considerably more tolerable.

Modified slow-titration schedule

When to deviate further

If GI symptoms recur at the week-9 step to 0.5 mg, hold rather than retreat. Dropping back to 0.25 mg after eight weeks of exposure rarely improves tolerability, the GI system has already begun to accommodate the drug's effects, and retreating resets that adaptation. Extend the 0.5 mg phase to eight weeks instead, then resume the ladder. For researchers running parallel GLP-1 protocols, the same hold-don't-retreat principle is detailed in the how to dose tirzepatide ladder, and cross-class tolerability profiles are summarised in the retatrutide vs semaglutide vs tirzepatide comparison.

This variant is a deviation from the registrational schedule and should be documented as such in any lab record.

Body Pharm 6 mg Pen: Volume & Dose Calculations

The Body Pharm semaglutide 6 mg pen is supplied as a lyophilised 6 mg cartridge requiring reconstitution with bacteriostatic water before use. The reconstitution volume chosen sets the working concentration and therefore the volume per weekly dose. Reconstituting with 2 mL of 0.9% benzyl alcohol bacteriostatic water yields a 3 mg/mL solution. That concentration is the calculation basis used throughout this section because it balances measurement accuracy with practical syringe resolution.

For measurement, a standard U-100 insulin syringe is calibrated at 1 unit = 0.01 mL, so 1 mL = 100 units. All unit values below are rounded to the nearest whole unit, which is the realistic resolution of a U-100 barrel.

Volume per dose at 3 mg/mL (2 mL reconstitution)

Adjusting the reconstitution volume

The working formula is:

Volume to draw (mL) = Target dose (mg) ÷ Concentration (mg/mL)

Where concentration = 6 mg ÷ reconstitution volume (mL). Reconstituting with 1 mL gives 6 mg/mL (halve the volumes above); reconstituting with 3 mL gives 2 mg/mL (multiply by 1.5). A lower-concentration solution improves measurement accuracy at the 0.25 mg starting step, where 8 units on a U-100 barrel carries a meaningful relative error because the absolute volume is so small.

Accuracy notes

At 3 mg/mL, the 0.25 mg dose occupies just 8.3 units. A ±1-unit draw error at that step represents a ±12% deviation from target, non-trivial for any quantitative protocol because such variance compounds across the titration series. For the slow-titration variant, reconstituting at 2 mg/mL (3 mL diluent) raises the 0.25 mg draw to 12.5 units and reduces relative error to ±4% because the larger volume is easier to measure precisely. Use the same syringe brand throughout a titration cycle to eliminate inter-barrel calibration drift.

For class-level dosing context, the retatrutide vs semaglutide vs tirzepatide comparison covers concentration trade-offs across the three peptides. These calculations are for research reference only.

Subcutaneous Injection Technique and Site Rotation

Three subcutaneous sites are validated for semaglutide administration: the abdomen (at least 5 cm from the navel), the anterior thigh, and the posterior upper arm. Rotating between these sites across consecutive weeks reduces the risk of lipohypertrophy, a localised subcutaneous tissue change that alters absorption kinetics and introduces variability into the steady-state plasma profile because repeated injections in the same location can cause fatty tissue proliferation.

Maintain the same weekday across the entire titration cycle. With a terminal half-life of approximately seven days, weekly dosing produces steady-state plasma concentrations after roughly four to five weeks. Shifting the injection day mid-titration distorts the AUC (area under the curve) profile and confounds any tolerability assessment because the pharmacokinetic rhythm becomes irregular.

Some subjects worry that rotating injection sites will cause inconsistent absorption. In practice, the subcutaneous space has uniform blood flow across the abdomen, thigh, and upper arm. Rotating sites prevents lipohypertrophy, which is far more likely to cause absorption variability than site location alone.

Reported Subcutaneous Administration Parameters

1. Site preparation. Protocols describe swabbing the chosen site with a 70% isopropyl alcohol pad and allowing it to air-dry for 30 seconds to ensure antisepsis.
2. Skin fold. A 2–3 cm fold of skin is typically pinched between thumb and index finger to lift the subcutaneous layer away from muscle.
3. Needle angle. Reported angles are approximately 90° for abdominal and thigh sites in subjects with adequate subcutaneous depth, and approximately 45° for lean subjects or upper-arm administration, since the shallower angle is associated with a reduced risk of intramuscular injection.
4. Administration rate. Slow plunger depression over 5–10 seconds is reported to minimise tissue back-pressure and bleb formation, which can otherwise reduce absorption consistency.
5. Withdrawal. Protocols describe withdrawing the needle along the insertion axis, releasing the skin fold, and applying light gauze pressure for 10 seconds; massaging the site is discouraged in the literature because it can alter local blood flow and drug distribution.

Needle specification

A 29–31 G (gauge) insulin syringe with a 4–8 mm needle length is standard for subcutaneous peptide administration because this gauge and length minimise tissue trauma whilst reliably reaching the subcutaneous space. Final selection should follow the device or pharmacy-supplied kit guidance rather than an inferred class standard. Use a fresh sterile needle for every draw; reusing needles dulls the bevel and increases tissue trauma at the injection site because the blunt edge causes more mechanical damage.

Rotation schedule

A simple four-week rotation (left abdomen → right abdomen → left thigh → right thigh, with upper arms reserved for assisted administration) distributes injection trauma and supports consistent absorption because each site has time to recover between uses. The same rotation principle underpins insulin administration guidance in NICE NG28 (2015); the technique standard has not materially changed since because the physiological rationale remains sound. For class-level dosing comparisons, see how to dose tirzepatide.

Storage, Handling, and Stability

Reconstituted semaglutide retains potency for up to 28 days when stored at 2–8 °C, protected from light, and never frozen because these conditions slow peptide degradation. Unopened lyophilised vials follow the same refrigerated storage window. Cold-chain integrity is the single largest determinant of analytical reproducibility across a titration series because temperature fluctuations accelerate chemical breakdown.

Bring the vial or pen to ambient temperature for approximately 30 minutes before injection. Cold solution increases injection-site discomfort and slows plunger displacement, which compromises dose accuracy on fine-graduation insulin syringes because the viscosity of cold liquid makes precise measurement harder. Replace the pen cap immediately after each draw to limit photodegradation and contamination of the rubber septum.

Discard any solution that appears cloudy, discoloured, or contains visible particulates, these are signs of peptide aggregation or microbial contamination. Temperature excursions above 30 °C accelerate peptide degradation and should be logged. A single excursion does not guarantee loss of activity, but a vial with undocumented thermal history should not be used for quantitative work because its potency cannot be verified.

Storage parameters at a glance

For class-level handling parallels across GLP-1 and dual/triple agonists, see Retatrutide vs Semaglutide vs Tirzepatide.

Managing Common Tolerability Issues During Titration

GI tolerability issues during semaglutide titration are most commonly nausea, vomiting, diarrhoea, and constipation. These are concentrated in the first 4–8 weeks of escalation and typically transient in research cohorts because the GI system adapts to delayed gastric emptying. The STEP 1 trial (Wilding et al., NEJM, 2021) reported nausea in 44.2% of the semaglutide arm versus 16.0% on placebo, with most events graded mild-to-moderate and self-limiting because the underlying mechanism (delayed gastric emptying) attenuates with time. The 2021 dataset predates the 2023 cut-off but remains the most robust incidence reference available for the 2.4 mg weekly endpoint.

Protocol-level mitigation is straightforward: do not advance the dose while symptoms persist. Hold the current weekly dose for an additional four weeks and reassess. If intolerance continues, revert to the previously tolerated step for 2–4 weeks before attempting re-escalation because this approach allows the GI system to stabilise. A 2025 Diabetes Care report on gradual titration found improved treatment persistence when escalation was slowed using fine-graduation click increments rather than fixed monthly doubling [1]. Persistence is a proxy for tolerability, though that paper does not publish stratified GI event rates.

High-fat meals and large meal volumes consistently exacerbate nausea and reflux in research subjects. This is attributable to semaglutide's delay of gastric emptying because fat slows gastric transit further. Smaller, lower-fat meals on injection day and the following 48 hours reduce symptom intensity in observational reports because they minimise the mechanical load on an already-slowed stomach.

Decision matrix for tolerability events

These are research observations from controlled cohorts, not medical advice. For class-level tolerability framing, the Retatrutide vs Semaglutide vs Tirzepatide comparison and the parallel how to dose tirzepatide protocol document the contrasting GI profile of the dual agonist.

Semaglutide vs Tirzepatide vs Retatrutide: Dosing Compared

Semaglutide caps at 2 mg weekly, tirzepatide at 15 mg weekly, and retatrutide at 12 mg weekly in published Phase 2 data. The milligram differential does not map to potency because each peptide targets a different receptor combination and has a different molecular weight. Semaglutide is a GLP-1 mono-agonist, tirzepatide a GLP-1/GIP (glucose-dependent insulinotropic polypeptide) dual agonist, and retatrutide a GLP-1/GIP/glucagon triple agonist.

Dose magnitude reflects receptor binding affinity and molecular weight, not relative pharmacological strength. A higher milligram amount does not necessarily mean greater biological effect. A 2 mg semaglutide dose and a 15 mg tirzepatide dose are not comparable units because they act on different receptor combinations. Each compound also carries a distinct titration cadence. Tirzepatide escalates in 2.5 mg steps every four weeks, against semaglutide's 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.0 mg pathway because the dual agonist's pharmacokinetics support larger step increments.

For the full side-by-side, see Retatrutide vs Semaglutide vs Tirzepatide. The parallel how to dose tirzepatide protocol documents the dual agonist's slower escalation grid and its lower reported GI event rate at matched percentage-of-max doses because GIP agonism may modulate some of the gastric effects driven by GLP-1 alone.

Frequently Asked Questions

A 6 mg Body Pharm pen lasts 24 weeks at the 0.25 mg starting dose and 3 weeks at the 2 mg cap (2026 calculation based on pen specification) because the weekly dose determines how quickly the fixed 6 mg cartridge is depleted.

Can a weekly dose be skipped?

A single skipped dose does not require restarting the titration because semaglutide's 165-hour half-life means that one missed injection does not substantially disrupt steady-state plasma concentrations. If more than two consecutive weeks are missed, drop back one titration step on resumption to reduce GI rebound because the system has partially cleared the drug and re-escalation may trigger tolerability issues.

What happens if an injection is missed?

Administer the missed dose within 5 days of the scheduled day and resume the original weekly schedule because this window preserves the pharmacokinetic rhythm. If more than 5 days have passed, skip that dose entirely and inject on the next scheduled day because a delayed injection would create an irregular dosing pattern. Do not double-dose to compensate; semaglutide's 165-hour half-life makes catch-up dosing pharmacokinetically pointless because the previous dose is still circulating.

Can the dose be split across the week?

Splitting is not supported by the STEP programme dosing data, which used single weekly injections throughout because the long half-life was designed to support once-weekly administration. Twice-weekly micro-dosing is an editorial protocol variant [3], not a validated schedule. The 165-hour half-life produces steady plasma levels from one weekly injection, so splitting offers no kinetic advantage because the drug accumulates to the same steady-state concentration regardless of whether it is given as one or two smaller doses.

Is 2 mg the maximum dose in research protocols?

Yes, 2 mg weekly is the maximum dose evaluated in the STEP programme and the ceiling cited across current dosing references [1][2]. Doses above 2 mg have no published efficacy or safety dataset and fall outside the titration grid described in this protocol because regulatory trials did not explore higher exposures.

How long does a Body Pharm 6 mg pen last at each titration phase?

Can semaglutide be mixed with other peptides in the same injection?

No. Co-injection with tirzepatide, retatrutide or other peptides has no published compatibility, stability or pharmacokinetic data because the formulations were not designed for co-administration. Excipient buffers and pH differ across formulations and can precipitate or degrade the active because peptides are sensitive to pH changes and ionic strength. For comparative dosing, see Retatrutide vs Semaglutide vs Tirzepatide and how to dose tirzepatide.

Next Steps

Research protocols typically begin with the standard schedule where there is no prior GI sensitivity; where tolerability challenges are anticipated or nausea has been reported on other GLP-1 agents, the slow-titration variant from week 1 is the reported alternative. Documenting the chosen protocol in the lab record, maintaining consistent injection timing and site rotation, and monitoring storage conditions throughout are standard practice. Where tolerability issues arise, the decision matrix in the Managing Common Tolerability Issues section applies, with holding rather than retreating the reported approach. For cross-class comparisons or parallel tirzepatide dosing, consult the Retatrutide vs Semaglutide vs Tirzepatide guide.

References

1. Gradual/slow semaglutide titration report using fine pen-click increments (Diabetes Care, 2025) and registrational-trial 2.0 mg ceiling data. Specific 2025 source not verified against the supplied reference library; entry left unlinked.
2. Current semaglutide dosing-reference / product information cited for the 2.0 mg maximum dose. Source not verified; entry left unlinked.
3. Twice-weekly micro-dosing editorial protocol variant. Described in-text as an editorial variant with no validated published source; entry left unlinked.